Vertex Minerals has initiated the commissioning of a newly installed ore sorter/pre-concentrator at its Hill End Gold plant ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved ...

Google has released a whole new range of AI-powered research and interactions that simply can't be matched by DeepSeek or OpenAI.

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

To define a modern curve for normal labor, these researchers evaluated data on 1329 nulliparous, full-term women with spontaneous labors and vertex presentations who gave birth to singletons of ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

The tech world is buzzing with exciting developments and innovations every day, let's find out what's new has been introduced ...